← Back to Search

Cartilage Matrix

Group II for Osteochondral Defect

N/A
Waitlist Available
Research Sponsored by St. Paul's Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up there are 6 assessment time points: within 21 days of surgery, 6 weeks post-op, 12 weeks post-op, 6 months post-op, 1 year post-op and 2 years post-op.
Awards & highlights

Study Summary

This trial tests whether adding a cartilage matrix product to microfracture treatment of ankle cartilage defects improves healing and pain/function.

Eligible Conditions
  • Osteochondral Defect

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcome will be administered 6 times per patient: within 21 days of surgery, 6 weeks post-op, 12 weeks post-op, 6 months post-op, 1 year post-op and 2 years post-op.
This trial's timeline: 3 weeks for screening, Varies for treatment, and outcome will be administered 6 times per patient: within 21 days of surgery, 6 weeks post-op, 12 weeks post-op, 6 months post-op, 1 year post-op and 2 years post-op. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes as Assessed by Ankle Osteoarthritis Scale (AOS)
Secondary outcome measures
CT radiographic assessments performed pre-operatively and post-operatively
Ankle
MRI radiographic assessments performed pre-operatively and post-operatively
+3 more

Trial Design

2Treatment groups
Active Control
Group I: Group IIActive Control1 Intervention
Group II consists of 10 patients receiving a microfracture with BioCartilage®.
Group II: Group IActive Control1 Intervention
Group I consists of 5 patients receiving a microfracture as per standard of care.

Find a Location

Who is running the clinical trial?

St. Paul's Hospital, CanadaLead Sponsor
44 Previous Clinical Trials
12,705 Total Patients Enrolled
Arthrex, Inc.Industry Sponsor
44 Previous Clinical Trials
29,867 Total Patients Enrolled

Media Library

BioCartilage® Micronized Cartilage Matrix (Cartilage Matrix) Clinical Trial Eligibility Overview. Trial Name: NCT03696394 — N/A
Osteochondral Defect Research Study Groups: Group II, Group I
Osteochondral Defect Clinical Trial 2023: BioCartilage® Micronized Cartilage Matrix Highlights & Side Effects. Trial Name: NCT03696394 — N/A
BioCartilage® Micronized Cartilage Matrix (Cartilage Matrix) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03696394 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this study still available to participants?

"Affirmative. The information posted on clinicaltrials.gov verifies that this research is actively seeking participants, with the first posting having been made on January 29th 2019 and most recently updated April 2nd of last year. This study requires 15 individuals to be recruited from 1 medical centre."

Answered by AI

How many participants are included in the clinical trial?

"Affirmative. According to information located on clinicaltrials.gov, this medical experiment is still searching for participants since its initial posting on January 29th 2019 and the latest update being April 2nd 2019. The study requires 15 patients from a single location."

Answered by AI

Who else is applying?

What site did they apply to?
St. Paul's Hospital
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

Since the first surgery was not successful I am looking for other options that might have better long term outcomes.
PatientReceived no prior treatments
~2 spots leftby Apr 2025